Old Drug, New Data: Broadening the Therapeutic Armamentarium for Desmoid Tumors
- 27 March 2026
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2127-2129
Abstract
Summary: Desmoid tumors are a locally invasive neoplasm that can exhibit unpredictable clinical behavior. Although treatment options are numerous, few are supported by level 1 evidence. A recent phase III trial evaluated the efficacy of long-used pegylated liposomal doxorubicin in patients with progressive desmoid tumors. See related article by Xu et al., p. 2198Keywords
This publication has 4 references indexed in Scilit:
- Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational StudiesClinical Cancer Research, 2024
- Nirogacestat, a γ-Secretase Inhibitor for Desmoid TumorsNew England Journal of Medicine, 2023
- The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patientsEuropean Journal of Cancer, 2020
- Sorafenib for Advanced and Refractory Desmoid TumorsNew England Journal of Medicine, 2018